E-MEXP-3625 - Translational profiling of non-muscle invasive bladder cancer tumor samples to identifiy proteins differentially expressed in recurrent and non-recurrent samples

Released on 7 April 2014, last updated on 3 May 2014
Homo sapiens
Samples (25)
Array (1)
Protocols (7)
Although non muscle-invasive bladder cancer can be treated successfully by surgical resection, there is a high rate of recurrence, which frequently develops into an invasive form of cancer. Due to the lack of marker molecules to predict recurrence, it is currently recommended that after resection each patient is screened via cystoscopy at least twice a year. This results in a psychic burden to the patient and substantial economic costs to the health care system. Using antibody microarrays targeting 724 different cancer-related proteins, we studied protein profiles of patients with and without recurrence. The analysis revealed 255 proteins of differential abundance. Most are involved in the regulation and execution of apoptosis and cell proliferation. For prognosis, a signature of 20 proteins was determined that predicts bladder cancer recurrence with 100% sensitivity and 80% specificity. As a measure of overall accuracy, the area under the curve (AUC) value was found to be 90%. This is well within a clinically relevant window of quality and should support decision making about the stringency of surveillance or even different treatment options.
Experiment types
transcription profiling by array, co-expression, disease state, ex vivo, reference
Investigation descriptionE-MEXP-3625.idf.txt
Sample and data relationshipE-MEXP-3625.sdrf.txt
Raw data (1)E-MEXP-3625.raw.1.zip
Array designA-MEXP-2202.adf.txt